CoronaVac

CoronaVac

Coronavac (Brazilian version) 2021 A

Covid vaccine clinical trial with Ridwan kamil.jpg

Error creating thumbnail:

Chegada do quarto lote com 5,5 milhões de doses da Vacina do Butantan (50753419378)

CoronaVac is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It is one of several vaccines developed to combat the COVID-19 pandemic and has been widely used in various countries around the world.

Development and Approval

CoronaVac was developed using a traditional method of vaccine production, which involves inactivating the SARS-CoV-2 virus with chemicals so that it cannot cause disease. This method has been used for decades in the production of vaccines for other diseases such as influenza and hepatitis A. The vaccine underwent several phases of clinical trials to assess its safety and efficacy. Phase I and II trials were conducted in China, while Phase III trials were carried out in multiple countries, including Brazil, Turkey, Indonesia, and Chile. The results of these trials demonstrated that CoronaVac is effective in preventing symptomatic COVID-19, although the reported efficacy rates varied between studies. CoronaVac received emergency use authorization in several countries, including China, Brazil, Indonesia, and Turkey. It has also been granted World Health Organization (WHO) Emergency Use Listing, which allows for its distribution through the COVAX initiative.

Mechanism of Action

CoronaVac works by exposing the immune system to the inactivated SARS-CoV-2 virus, which stimulates the production of antibodies without causing the disease. This immune response helps the body recognize and fight the virus if it is encountered in the future.

Distribution and Use

CoronaVac has been distributed to numerous countries, particularly in Asia, South America, and Africa. It has been a crucial component of the vaccination campaigns in countries with limited access to other COVID-19 vaccines. The vaccine is administered in two doses, typically given two to four weeks apart.

Efficacy and Safety

The efficacy of CoronaVac has been a subject of extensive study and debate. Clinical trials have reported varying efficacy rates, with some studies showing around 50% efficacy in preventing symptomatic COVID-19, while others have reported higher rates. Despite these variations, the vaccine has been shown to be effective in preventing severe disease and hospitalization. The safety profile of CoronaVac is similar to other inactivated vaccines. Common side effects include pain at the injection site, fatigue, and mild fever. Serious adverse events are rare.

Public Perception and Impact

CoronaVac has played a significant role in the global effort to control the COVID-19 pandemic, especially in countries with limited access to other vaccines. Its use has helped to reduce the burden of the disease and has been a key tool in achieving higher vaccination coverage in many regions.

See Also

• COVID-19 vaccine
• Sinovac Biotech
• SARS-CoV-2
• World Health Organization
• COVAX